Floatz logo

144 assets in Colorectal Carcinoma

Therapeutic assets addressing Colorectal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Tipiracil
Colorectal Carcinoma
Mayo ClinicP2BBB (73)
Fluorouracilum
Colorectal Carcinoma
City of Hope Medical CenterP4BB (70)
Oxaliplatin
Colorectal Carcinoma
First Affiliated Hospital of Zhejiang UniversityP4BB (68)
Muamycin
Colorectal Carcinoma
City of Hope Medical CenterP3BB (67)
Capecitabine
Colorectal Carcinoma
First Affiliated Hospital of Zhejiang UniversityP4BB (66)
Irinotecan
Colorectal Carcinoma
City of Hope Medical CenterP3BB (65)
Pentoxifylline
Colorectal Carcinoma
Tanta UniversityP4BB (65)
Cetuximab
Colorectal Carcinoma
Shanghai Changzheng HospitalP3BB (64)
Cyclophosphamide
Colorectal Carcinoma
City of Hope Medical CenterP3BB (64)
Durvalumab
Colorectal Carcinoma
Gruppo Oncologico del Nord-OvestP2BB (64)
Pembrolizumab
Colorectal Carcinoma
Roswell Park Cancer InstituteP3BB (64)
Trifluridine
Colorectal Carcinoma
Mayo ClinicP2BB (64)
Nivolumab
Colorectal Carcinoma
Fred Hutchinson Cancer CenterP2B (63)
Regorafenib
Colorectal Carcinoma
City of Hope Medical CenterP2B (63)
Compound Kushen Injection
Colorectal Carcinoma
Guang'anmen Hospital of China Academy of Chinese Medical SciencesP4B (62)
Encorafenib
Colorectal Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCSP2B (61)
Panitumumab
Colorectal Carcinoma
Federation Francophone de Cancerologie DigestiveP3B (61)
Balstilimab
Colorectal Carcinoma
City of Hope Medical CenterP2B (60)
Botensilimab
Colorectal Carcinoma
City of Hope Medical CenterP2B (60)
Tislelizumab
Colorectal Carcinoma
Fudan UniversityP2B (60)
Fludarabine
Colorectal Carcinoma
City of Hope Medical CenterP2B (59)
Nepenthe
Colorectal Carcinoma
Meri MircetaP4B (59)
Binimetinib
Colorectal Carcinoma
Roswell Park Cancer InstituteP2B (58)
Floxuridine
Colorectal Carcinoma
ECOG-ACRIN Cancer Research GroupP3B (58)
Fruquintinib
Colorectal Carcinoma
Fudan UniversityP2B (58)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
Colorectal Carcinoma
National Cancer Institute (NCI)P2B (58)
Palbociclib
Colorectal Carcinoma
Roswell Park Cancer InstituteP2B (58)
Trametinib
Colorectal Carcinoma
Novartis PharmaceuticalsP2B (58)
Trastuzumab Deruxtecan
Colorectal Carcinoma
Gruppo Oncologico del Nord-OvestP2B (58)
Dasatinib
Colorectal Carcinoma
Anne NoonanP2B (57)
Pixatimod
Colorectal Carcinoma
Diwakar DavarP2B (57)
Ipilimumab
Colorectal Carcinoma
Incyte CorporationP1/2B (56)
Tas-102
Colorectal Carcinoma
University of California, IrvineP2CCC (55)
Abemaciclib
Colorectal Carcinoma
National Cancer Institute (NCI)P1/2CCC (54)
Alpha Tocopherol
Colorectal Carcinoma
Fudan UniversityP2CCC (53)
Amivantamab-Vmjw
Colorectal Carcinoma
Gruppo Oncologico del Nord-OvestP2CCC (53)
Danvatirsen
Colorectal Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Darizmetinib
Colorectal Carcinoma
Mayo ClinicP2CCC (53)
Hydroxychloroquine
Colorectal Carcinoma
Northwestern UniversityP2CCC (53)
Niraparib
Colorectal Carcinoma
Emory UniversityP2CCC (53)
oh2
Colorectal Carcinoma
Binhui Biopharmaceutical Co., Ltd.P2CCC (53)
Olanzapine
Colorectal Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Serplulimab
Colorectal Carcinoma
First Affiliated Hospital of Zhejiang UniversityP2CCC (53)
Vorbipiprant
Colorectal Carcinoma
Gruppo Oncologico del Nord-OvestP2CCC (53)
ad5 cea vaccine
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Adenovirus 5 Cea/Muc1/Brachyury Vaccine Tri-Ad5
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Aspirin
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Atorvastatin
Colorectal Carcinoma
Northwestern UniversityP2CCC (51)
Capivasertib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Crizotinib
Colorectal Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Showing 1 to 50 of 144 assets
PreviousPage 1 of 3Next